Stand out for this role — generate a tailored resume and cover letter in about a minute.
Replimune is seeking a Sr. Scientist Analytical Development to lead method development, qualification, and validation for drug substance and product from preclinical to late-stage clinical development.
The role requires coordination with CMOs/CROs, regulatory filings support, and hands-on data analysis to ensure robust analytical capabilities within a cGMP setting. Based in Milton Park, on-site 5 days a week.
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to impact on the lives of patients, caregivers and themselves.
Sr. Scientist Analytical Development is responsible for developing, optimizing, qualifying, and validating analytical methods based on new and existing methodologies to qualitatively and quantitatively evaluate both drug substance and drug product, from preclinical through late phase clinical development. Analytical development supports drug substance/drug product release, process development, and characterization and/or stability testing of Replimune’s clinical material. In addition, coordination of analytical development and analysis work at CMOs/CROs will be a significant portion of the duties of the Sr. Scientist Analytical Development.
Education will be appropriate to specific job requirements. The following educational requirements are a minimum:
Training and experience will be appropriate to specific job requirements. The following categories will be assessed in each case:
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com. We are an Equal Opportunity Employer.